Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $4.3 million.

  • 4D Molecular Therapeutics' Other Non-Current Assets rose 227.51% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 227.51%. This contributed to the annual value of $4.3 million for FY2024, which is 522.95% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Other Non-Current Assets of $4.3 million as of FY2024, which was up 522.95% from $684,000 recorded in FY2023.
  • 4D Molecular Therapeutics' Other Non-Current Assets' 5-year high stood at $4.3 million during FY2024, with a 5-year trough of $602,000 in FY2020.
  • In the last 3 years, 4D Molecular Therapeutics' Other Non-Current Assets had a median value of $1.1 million in 2022 and averaged $2.0 million.
  • In the last 5 years, 4D Molecular Therapeutics' Other Non-Current Assets plummeted by 36.67% in 2023 and then soared by 522.95% in 2024.
  • 4D Molecular Therapeutics' Other Non-Current Assets (Yearly) stood at $602,000 in 2020, then remained steady at $602,000 in 2021, then surged by 79.40% to $1.1 million in 2022, then crashed by 36.67% to $684,000 in 2023, then soared by 522.95% to $4.3 million in 2024.